Trials / Completed
CompletedNCT02628379
Outcomes of FoundationOne Directed Therapy in Cancer of Unknown Primary
A Prospective Observational Trial Evaluating Outcomes of FoundationOne - Directed Matched Targeted Therapy in Patients With Cancer of Unknown Primary (CUP)
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 125 (actual)
- Sponsor
- Foundation Medicine · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of the current study is to determine whether Foundation Medicine's next generation sequencing assay, called FoundationOne, will provide information that allows physicians to make treatment decisions using targeted therapies in clinical trials or FDA approved therapies, including "off-label" agents, that result in superior OS compared to historical outcomes for standard CUP therapy.
Conditions
- Neoplasms, Unknown Primary
- CUP
- Metastatic Disease
- Poorly Differentiated Adenocarcinoma
- Poorly Differentiated Carcinoma
- Squamous Carcinoma Poorly Differentiated
Timeline
- Start date
- 2015-05-01
- Primary completion
- 2017-03-01
- Completion
- 2017-03-01
- First posted
- 2015-12-11
- Last updated
- 2018-07-10
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02628379. Inclusion in this directory is not an endorsement.